OneSource Specialty Pharma's Partner Gets US FDA Nod for Generic Version of Ozempic

MT Newswires Live04-21

OneSource Specialty Pharma's (NSE:ONESOURCE, BOM:544292) partner Orbicular has received tentative approval from US Food and Drug Administration (US FDA) for a generic version of Ozempic (Semaglutide injection), according to a Tuesday filing to the Indian stock exchanges.

OneSource is the contract development and manufacturing organization (CDMO) partner for the complex peptide.

Orbicular led its product development and technical program, while OneSource supported the program as the CDMO partner, providing end-to-end manufacturing capabilities for the US market filing.

The collaboration will help to ensure a reliable commercial supply from OneSource's US FDA site in Bangalore, India.

The company's shares were down over 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629546700?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 14:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629546700","market":"us","top_or_hot":-1,"title":"OneSource Specialty Pharma's Partner Gets US FDA Nod for Generic Version of Ozempic","media":"MT Newswires Live","content":"<html><body><p> OneSource Specialty Pharma's (NSE:ONESOURCE, BOM:544292) partner Orbicular has received tentative approval from US Food and Drug Administration (US FDA) for a generic version of Ozempic (Semaglutide injection), according to a Tuesday filing to the Indian stock exchanges.</p><p>OneSource is the contract development and manufacturing organization (CDMO) partner for the complex peptide.</p><p>Orbicular led its product development and technical program, while OneSource supported the program as the CDMO partner, providing end-to-end manufacturing capabilities for the US market filing.</p><p>The collaboration will help to ensure a reliable commercial supply from OneSource's US FDA site in Bangalore, India.</p><p>The company's shares were down over 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OneSource Specialty Pharma's Partner Gets US FDA Nod for Generic Version of Ozempic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOneSource Specialty Pharma's Partner Gets US FDA Nod for Generic Version of Ozempic\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-21 14:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> OneSource Specialty Pharma's (NSE:ONESOURCE, BOM:544292) partner Orbicular has received tentative approval from US Food and Drug Administration (US FDA) for a generic version of Ozempic (Semaglutide injection), according to a Tuesday filing to the Indian stock exchanges.</p><p>OneSource is the contract development and manufacturing organization (CDMO) partner for the complex peptide.</p><p>Orbicular led its product development and technical program, while OneSource supported the program as the CDMO partner, providing end-to-end manufacturing capabilities for the US market filing.</p><p>The collaboration will help to ensure a reliable commercial supply from OneSource's US FDA site in Bangalore, India.</p><p>The company's shares were down over 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2629546700","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629546700","pubTimestamp":1776753046,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"OneSource Specialty Pharma's (NSE:ONESOURCE, BOM:544292) partner Orbicular has received tentative approval from US Food and Drug Administration (US FDA) for a generic version of Ozempic (Semaglutide i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技","CDMO":"Avid Bioservices, Inc."},"translate_title":"OneSource Specialty Pharma的合作伙伴获得美国FDA批准Ozempic仿制药","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDMO":1,"LABU":1.5},"content_text":"OneSource Specialty Pharma's (NSE:ONESOURCE, BOM:544292) partner Orbicular has received tentative approval from US Food and Drug Administration (US FDA) for a generic version of Ozempic (Semaglutide injection), according to a Tuesday filing to the Indian stock exchanges.OneSource is the contract development and manufacturing organization (CDMO) partner for the complex peptide.Orbicular led its product development and technical program, while OneSource supported the program as the CDMO partner, providing end-to-end manufacturing capabilities for the US market filing.The collaboration will help to ensure a reliable commercial supply from OneSource's US FDA site in Bangalore, India.The company's shares were down over 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629546700","isCrawlerRequest":true}